Synergistic effects between ATO and anti-PD-L1, which blocks binding of PD-L1 to its receptor PD-1, leads to the activation of tumor-reactive CD8+ T cells and promotes the establishment of tumor-specific immune memory (272). Here, PDCD1 is linked to neoplasm.